HER2 Status and Efficacy of Adjuvant Anthracyclines in Early Breast Cancer: A Pooled Analysis of Randomized Trials

蒽环类 医学 内科学 危险系数 乳腺癌 肿瘤科 随机对照试验 比例危险模型 置信区间 化疗 癌症 辅助治疗
作者
Alessandra Gennari,Maria Pia Sormani,P. Pronzato,Matteo Puntoni,Mariantonietta Colozza,Ulrich Pfeffer,Paolo Bruzzi
出处
期刊:Journal of the National Cancer Institute [Oxford University Press]
卷期号:100 (1): 14-20 被引量:367
标识
DOI:10.1093/jnci/djm252
摘要

Adjuvant chemotherapy with anthracyclines improves disease-free and overall survival compared with non-anthracycline-based adjuvant chemotherapy regimens in the treatment of early breast cancer. The role of HER2 status as a marker of anthracycline responsiveness has been explored by subset analyses within randomized clinical trials, with inconsistent results. We performed a pooled analysis of the interaction between HER2 status and the efficacy of adjuvant anthracyclines based on the published subset data.We searched literature databases to identify randomized trials that compared anthracycline-based with non-anthracycline-based adjuvant chemotherapy regimens in the treatment of early breast cancer and reported efficacy data according to HER2 status. Log hazard ratios (HRs) for disease-free and overall survival were pooled across the studies according to HER2 status by inverse variance weighting. A pooled test for treatment by HER2 status interaction was performed by weighted linear meta-regression. All statistical tests were two-sided.Eight studies (with 6564 randomly assigned patients, of whom 5354 had HER2 status information available) were eligible for this analysis. In HER2-positive disease (n = 1536 patients), anthracyclines were superior to non-anthracycline-based regimens in terms of disease-free (pooled HR of relapse = 0.71; 95% confidence interval [CI] = 0.61 to 0.83; P < .001) and overall (pooled HR of death from any cause = 0.73; 95% CI = 0.62 to 0.85; P < .001) survival. In HER2-negative disease (n = 3818 patients), anthracyclines did not improve disease-free (HR = 1.00; 95% CI = 0.90 to 1.11; P = .75) or overall (HR = 1.03; 95% CI = 0.92 to 1.16; P = .60) survival. The test for treatment by HER2 status interaction yielded statistically significant results: for disease-free survival, the chi-square statistic for interaction was 13.7 (P < .001), and for overall survival, it was 12.6 (P < .001).The added benefits of adjuvant chemotherapy with anthracyclines appear to be confined to women who have HER2 overexpressed or amplified breast tumors.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Mira完成签到,获得积分10
1秒前
温柔手机完成签到,获得积分10
1秒前
1秒前
Lindsay完成签到,获得积分10
2秒前
巧克力完成签到 ,获得积分10
2秒前
2秒前
2秒前
3秒前
3秒前
fengyuenanche完成签到,获得积分10
3秒前
3秒前
4秒前
5秒前
一瓶水发布了新的文献求助10
5秒前
橙子发布了新的文献求助10
5秒前
乐乐发布了新的文献求助20
6秒前
未来发布了新的文献求助10
6秒前
lalafish发布了新的文献求助10
7秒前
oyxz完成签到,获得积分10
7秒前
柔弱小之发布了新的文献求助10
7秒前
8秒前
Chemistry完成签到,获得积分10
8秒前
8秒前
niu发布了新的文献求助10
9秒前
简单的钢铁侠完成签到,获得积分10
9秒前
赘婿应助Demonmaster采纳,获得10
9秒前
张通发布了新的文献求助10
10秒前
拜拜拜仁完成签到,获得积分10
10秒前
10秒前
11秒前
11秒前
12秒前
12秒前
鱼儿会飞发布了新的文献求助10
12秒前
13秒前
七七发布了新的文献求助10
13秒前
13秒前
13秒前
小马过河发布了新的文献求助10
13秒前
大模型应助饱满的鑫采纳,获得10
14秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
Aktuelle Entwicklungen in der linguistischen Forschung 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3986829
求助须知:如何正确求助?哪些是违规求助? 3529292
关于积分的说明 11244137
捐赠科研通 3267685
什么是DOI,文献DOI怎么找? 1803843
邀请新用户注册赠送积分活动 881223
科研通“疑难数据库(出版商)”最低求助积分说明 808600